MDACC Study No:2008-0246 ( NCT No: NCT00880815)
Title:Fludarabine, Bendamustine and Rituximab (FBR) Non-myeloablative Allogeneic Conditioning for Patients with Lymphoid Malignancies
Principal Investigator:Issa F. Khouri
Treatment Agent:Antithymocyte Globulin; Bendamustine HCl; Fludarabine; Rituximab
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if bendamustine, when
given with a stem cell transplant and chemotherapy (fludarabine and rituximab),
can help the transplanted stem cells start to grow and make new blood cells in
patients with leukemia and lymphoma. The safety of this combination will also
be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia; Lymphoma
Phase of Study:Phase I
Treatment Agents:Antithymocyte Globulin
Bendamustine HCl
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:3-4 weeks in the hospital.
Supported By:Cephalon, Inc.
Return Visit:Every 3 months for the first year, then every 6 months while the patient is on
Home Care:N/A

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Issa F. Khouri
Dept:Stem Cell Transplantation and Cellular Therapy
For Clinical Trial Enrollment:713-792-8750
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults